TG Therapeutics Inc (TGTX) : Ra Capital Management scooped up 1,717,935 additional shares in TG Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 4,531,714 shares of TG Therapeutics Inc which is valued at $27,235,601.TG Therapeutics Inc makes up approximately 3.16% of Ra Capital Management’s portfolio.
Other Hedge Funds, Including , Alliancebernstein boosted its stake in TGTX in the latest quarter, The investment management firm added 15,500 additional shares and now holds a total of 61,240 shares of TG Therapeutics Inc which is valued at $368,052.Baldwin Brothers Incma boosted its stake in TGTX in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 15,850 shares of TG Therapeutics Inc which is valued at $95,259. TG Therapeutics Inc makes up approx 0.02% of Baldwin Brothers Incma’s portfolio. Oxford Asset Management added TGTX to its portfolio by purchasing 78,427 company shares during the most recent quarter which is valued at $449,387. TG Therapeutics Inc makes up approx 0.02% of Oxford Asset Management’s portfolio. Quadrant Capital Group sold out all of its stake in TGTX during the most recent quarter. The investment firm sold 598 shares of TGTX which is valued $3,534.
TG Therapeutics Inc opened for trading at $6.35 and hit $6.53 on the upside on Thursday, eventually ending the session at $6.51, with a gain of 2.52% or 0.16 points. The heightened volatility saw the trading volume jump to 2,17,118 shares. Company has a market cap of $355 M.
Many Wall Street Analysts have commented on TG Therapeutics Inc. SunTrust Initiated TG Therapeutics Inc on May 27, 2016 to “Buy”, Price Target of the shares are set at $18.
TG Therapeutics Inc. (TG) is a biopharmaceutical company focused on the acquisition development and commercialization of treatments for b-cell malignancies and autoimmune diseases. As of December 31 2014 TG had two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202 an orally available PI3K delta inhibitor. As of December 31 2014 both TG-1101 and TGR-1202 were in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop inhibitors of IRAK4 (interleukin-1 receptor-associated kinase 4) as well as an antibody research program to develop anti-PD-L1 and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies which were in pre-clinical development as of December 31 2014.